Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia.

We report a study of an alternative treatment schedule of imatinib (IM) in chronic myeloid leukemia (CML). Seventy-six Philadelphia-positive (Ph+), BCR-ABL-positive patients aged 65 years or older who had been treated with IM for more than 2 years and who were in stable complete cytogenetic response (CCgR) and major molecular response (MMR) were enrolled in a single-arm study to test the effects of a policy of intermittent IM (INTERIM) therapy for 1 month on and 1 month off. With a minimum follow-up of 4 years, 13 patients (17%) lost CCgR and MMR and 14 (18%) lost MMR only. All these patients resumed continuous IM and all but one (lost to follow-up) regained CCgR and MMR. No patients progressed to accelerated or blastic phase or developed clonal chromosomal abnormalities in Ph+ cells or BCR-ABL mutations. In elderly Ph+ CML patients carefully selected for a stable CCgR (lasting >2 years), the policy of INTERIM treatment affected the markers of residual disease, but not the clinical outcomes (overall and progression-free survival). This trial was registered at www.clinicaltrials.gov as NCT 00858806.

[1]  I. Flinn,et al.  Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up , 2012, Leukemia.

[2]  M. Baccarani,et al.  Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). , 2012, Blood.

[3]  H. Kantarjian,et al.  Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. , 2011, Blood.

[4]  D. Marin,et al.  The Natural History of RTQ-PCR Levels After the Achievement of Complete Molecular Remission (CMR): Implications for ‘Stopping' Studies , 2011 .

[5]  Simona Soverini,et al.  BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. , 2011, Blood.

[6]  M. Höglund,et al.  Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  F. Gherlinzoni,et al.  Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. , 2011, Blood.

[8]  Philippe Rousselot,et al.  Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. , 2010, The Lancet. Oncology.

[9]  J. Melo,et al.  Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR , 2010, Leukemia.

[10]  Ricardo Pasquini,et al.  Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. , 2010, The New England journal of medicine.

[11]  C. Carcassi,et al.  Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP. , 2009, Blood.

[12]  M. Baccarani,et al.  Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. , 2009, Blood.

[13]  M. Baccarani,et al.  Nilotinib 800 Mg Daily as Frontline Therapy of Ph + Chronic Myeloid Leukemia: Dose Delivered and Safety Profile for the GIMEMA CML Working Party. , 2009 .

[14]  N. Cross,et al.  Harmonization of molecular monitoring of CML therapy in Europe , 2009, Leukemia.

[15]  B. Druker,et al.  Translation of the Philadelphia chromosome into therapy for CML. , 2008, Blood.

[16]  Martin C. Müller,et al.  Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. , 2008, Blood.

[17]  J. Apperley.  Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. , 2007, The Lancet. Oncology.

[18]  J. Goldman.  How I treat chronic myeloid leukemia in the imatinib era. , 2007, Blood.

[19]  M. Deininger,et al.  Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. , 2007, Blood.

[20]  Andreas Hochhaus,et al.  Chronic myeloid leukaemia , 2007, The Lancet.

[21]  H. Kantarjian,et al.  Current and emerging treatment options in chronic myeloid leukemia , 2007, Cancer.

[22]  Francisco Cervantes,et al.  Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. , 2006, Blood.

[23]  Simona Soverini,et al.  Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. , 2006, Blood.

[24]  H. Cavé,et al.  Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer Program , 2003, Leukemia.

[25]  R. A’Hern.  Sample size tables for exact single‐stage phase II designs , 2001, Statistics in medicine.

[26]  J Crowley,et al.  Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. , 1999, Statistics in medicine.

[27]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[28]  M. Gordon.  Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia , 2010 .

[29]  L. Shaffer,et al.  ISCN 2009 - An International System for Human Cytogenetic Nomenclature , 2009 .

[30]  P. Erben,et al.  Resistance to targeted therapy in chronic myelogenous leukemia. , 2007, Seminars in hematology.